Amgen reports a 22% increase in Q1 2024 net revenues

Amgen announced updates in the obesity space, with topline data for MariTide expected in late 2024.

May 7, 2024 - 00:00

Amgen reports a 22% increase in Q1 2024 net revenues

Amgen announced updates in the obesity space, with topline data for MariTide expected in late 2024.

Read the original article

Tags:

Previous Article

Sentynl acquires Eiger’s Zokinvy for progeria treatment

Regeneron and Lilly Struggle with Clinical Objectives after Market Focus on Weig...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

FDA hearing set to discuss advisory committee members’ conflicts and more

FDA hearing set to discuss advisory committee members’ ...

Jun 6, 2024

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis

Health Canada approves Arcutis’ ZORYVE foam for seborrh...

Oct 22, 2024

STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity

STAT+: EU regulator recommends expanding diabetes drug ...

Nov 11, 2023